Loading…
Omeros Corporation is projected to rise to $17.45 by 2027, a +47% move from its current price of $11.84. OMER is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $11.28 | $11.85 | $12.44 | +0.08% |
| Aug 3 | $11.07 | $11.86 | $12.71 | +0.15% |
| Aug 4 | $10.90 | $11.87 | $12.91 | +0.23% |
| Aug 5 | $10.77 | $11.88 | $13.09 | +0.30% |
| Aug 6 | $10.66 | $11.88 | $13.26 | +0.38% |
| Aug 7 | $10.55 | $11.89 | $13.40 | +0.45% |
| Aug 8 | $10.46 | $11.90 | $13.54 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.46 | $11.90 | $13.54 | +0.53% |
| Week 2 | $9.97 | $11.97 | $14.36 | +1.06% |
| Week 3 | $9.62 | $12.03 | $15.05 | +1.60% |
| Week 4 | $9.34 | $12.09 | $15.66 | +2.14% |
| Week 5 | $9.11 | $12.16 | $16.23 | +2.68% |
| Week 6 | $8.91 | $12.22 | $16.77 | +3.23% |
| Week 7 | $8.73 | $12.29 | $17.29 | +3.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Omeros Corporation is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Its lead product candidate is Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA), with a Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. Omeros also develops OMS1029, which has completed Phase I clinical trials for MASP-2 and lectin pathway disorders, and OMS527, which is in Phase I clinical trials for addictions and compulsive disorders, movement disorders, and cocaine use disorder. In addition, the company maintains preclinical development programs including MASP-2 and MASP-3 inhibitors, OncotoX-AML, and Targeted Complement Activating Therapy for multidrug-resistant organisms.
Omeros Corporation (OMER) sits in the Healthcare sector with a current price of $11.34 and a market capitalization of $820.74M, ranking 2541 by market cap. The stock’s price environment is framed by a 30-day trading range of $7.92 to $16.24 and a technical picture that currently reads bullish overall.
The near-term outlook reflects a neutral stance for 2026, but the longer horizon shows a strong bullish trajectory, with year-by-year forecasts indicating meaningful upside over the next several years and decades. The projected average prices rise from $11.34 in 2026 to substantially higher levels by 2050, suggesting a multi-year uptrend amid ongoing clinical-stage developments and potential approvals in its therapeutic areas.
A major floor 36.2% below — a decisive break under it would weaken the trend.
The nearest floor, 26.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.8% away) — a breakout level to watch.
A major ceiling 27.2% above — clearing it would confirm fresh momentum.
Key OMER support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OMER market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.61 | Buy | $11.49 | Buy |
| MA 10 | $10.71 | Buy | $11.02 | Buy |
| MA 20 | $10.42 | Buy | $10.63 | Buy |
| MA 50 | $10.34 | Buy | $10.70 | Buy |
| MA 100 | $11.38 | Buy | $10.90 | Buy |
| MA 200 | $10.98 | Buy | $10.30 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.53 | Neutral |
| Stoch RSI (14) | 95.50 | Sell |
| CCI (20) | 156.69 | Buy |
| Williams %R (14) | -3.32 | Info |
| MACD (12,26,9) | 0.27 | Buy |
| ROC (12) | 14.18 | Buy |
| Bollinger %B (20,2) | 0.96 | Neutral |
| Stochastic %K (14) | 96.68 | Sell |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | 1.47 | Buy |
| Ultimate (7,14,28) | 72.70 | Sell |
| Momentum (10) | 2.15 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 12.22 | Sell |
| ADX (14) | 15.23 | Neutral |
| ATR (14) | 0.39 | Info |
The 30-day technical picture is bullish with a current sentiment labeled as BULLISH. RSI14 sits at 60, indicating modest positive momentum. The stock trades above the 50-day and 200-day simple moving averages, with SMA50 at $10.39 and SMA200 at $10.83.
Key support is identified at $8.67 and resistance at $11.34, placing current action near the upper band of near-term resistance. The 30-day range spans from a low of $7.92 to a high of $16.24, illustrating notable short-term volatility within today’s trading context.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.67 | $11.84 | $17.23 | 0% | Neutral | |
| $12.92 | $17.45 | $25.40 | +47% | Bullish | |
| $11.45 | $16.33 | $25.27 | +38% | Bullish | |
| $11.18 | $16.72 | $27.09 | +41% | Bullish | |
| $12.60 | $19.66 | $33.08 | +66% | Bullish | |
| $10.95 | $17.76 | $30.88 | +50% | Bullish | |
| $13.07 | $22.00 | $39.38 | +86% | Bullish | |
| $17.13 | $29.86 | $54.88 | +152% | Bullish | |
| $17.45 | $31.49 | $59.26 | +166% | Bullish | |
| $18.70 | $34.89 | $67.12 | +195% | Bullish | |
| $23.17 | $50.74 | $106.79 | +329% | Bullish | |
| $37.40 | $83.11 | $191.15 | +602% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.67 | $11.84 | $14.28 | +0.00% |
| September 2026 | $10.15 | $12.29 | $15.50 | +3.80% |
| October 2026 | $10.34 | $12.69 | $16.30 | +3.22% |
| November 2026 | $10.08 | $12.49 | $16.28 | -1.58% |
| December 2026 | $10.43 | $13.04 | $17.23 | +4.45% |
Click any year to see its month-by-month OMER forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The OMER price prediction for 2026 points to an average of $11.84 (low $8.67, high $17.23) — a potential gain of 0% on today's $11.84. Price action looks broadly range-bound.
In 2027, OMER is projected to trade between $12.92 and $25.40, averaging $17.45 — a potential gain of +47% from today's $11.84. That is up +47% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Omeros Corporation's 2028 outlook centres on $16.33, within a $11.45 to $25.27 range. That is -6% versus the projected 2027 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2029, OMER could reach as high as $27.09, with a base case around $16.72 and support toward $11.18 — roughly +41% from $11.84. Buyers look set to stay in control over this stretch.
Expect OMER to range from $12.60 to $33.08 through 2030. The $19.66 average target implies a +66% move from current prices. That is up +18% on the projected 2029 average. Momentum favours further upside here.
The OMER price prediction for 2031 points to an average of $17.76 (low $10.95, high $30.88) — a potential gain of +50% on today's $11.84. Buyers look set to stay in control over this stretch.
In 2032, OMER is projected to trade between $13.07 and $39.38, averaging $22.00 — a potential gain of +86% from today's $11.84. That is up +24% on the projected 2031 average. Momentum favours further upside here.
Omeros Corporation's 2033 outlook centres on $29.86, within a $17.13 to $54.88 range. That is up +36% on the projected 2032 average. That marks a +152% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, OMER could reach as high as $59.26, with a base case around $31.49 and support toward $17.45 — roughly +166% from $11.84. Momentum favours further upside here.
Expect OMER to range from $18.70 to $67.12 through 2035. The $34.89 average target implies a +195% move from current prices. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The OMER price prediction for 2040 points to an average of $50.74 (low $23.17, high $106.79) — a potential gain of +329% on today's $11.84. Momentum favours further upside here.
In 2050, OMER is projected to trade between $37.40 and $191.15, averaging $83.11 — a potential gain of +602% from today's $11.84. That is up +64% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in OMER today (≈ 84.459459 OMER) could be worth
$7,019.34
+$6,019.34 (+602%) by 2050 · US Dollar
Based on the average projected OMER price of $83.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OMERwould be worth at today's price.
$1,000 invested in OMER on Jul 31, 2025 (≈ 258.39794 OMER) would be worth
$3,059.43
+$2,059.43 (+205.9%) today · 3.06× · US Dollar
Based on a OMER entry price of $3.87 vs. today's $11.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.79 | $1,209.4 | +20.9% |
| 1 month ago | $9.41 | $1,258.24 | +25.8% |
| 3 months ago | $15.06 | $786.19 | -21.4% |
| 6 months ago | $11.72 | $1,010.24 | +1.0% |
| 1 year ago | $3.87 | $3,059.43 | +205.9% |
| All time (5.0y) ago | $14.98 | $790.39 | -21.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OMER forecast.
Our base-case forecast reaches $24.00 around 2033.
Implied market cap at $24.00: $1.74B
Looking at the multi-year forecast, the path shows increasing averages and strong upside potential. For 2026, the min is $8.67, the avg is $11.34, the max is $16.94, with an ROI of 0 and a NEUTRAL sentiment. In 2027, the min rises to $12.35, the avg to $16.96, and the max to $25.20, with an ROI of 49.6 and a BULLISH sentiment.
The upside continues through 2028 and 2029 with avg prices of $15.41 and $15.66 respectively, and ROIs of 35.9 and 38.1. By 2030, the forecast shows an avg price of $18.15, a min of $11.24, a max of $31.44, an ROI of 60, and a BULLISH sentiment. In 2031–2035 the averages ramp to the mid- to upper-$20s with substantial ROIs (e.g., 2033 avg $26.77, ROI 136.1; 2034 avg $28.07, ROI 147.6; 2035 avg $31.32, ROI 176.2).
The long-range view is markedly positive, with 2040 showing an avg of $43.23 and a max of $94.83 (ROI 281.2) and 2050 projecting an avg of $69.95 and a max of $160.88 (ROI 516.8), all indicating bullish sentiment. These projections come with inherent uncertainty, but they illustrate a clear upward trajectory across multiple milestones. The asset exhibits high volatility, indicated by an annualized volatility of 100%.
Drivers include ongoing clinical programs and potential regulatory milestones within its MASP-2/lectin pathway focus; risks include the general uncertainties of clinical-stage asset development and market conditions.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $18.15, with a min of $11.24 and a max of $31.44, and an estimated ROI of 60% with a bullish sentiment.
The forecast depicts bullish sentiment in multiple years after 2026, with rising average prices (e.g., $16.96 in 2027, $43.23 by 2040, and $69.95 by 2050) and high potential ROIs (up to 516.8% in 2050). These are estimates, not guarantees, and should be weighed against risks and individual investment objectives.
Yes. The forecast shows a max of $50.91 in 2033 and $54.74 in 2034, with higher maxima in later years (e.g., $62.49 in 2035 and beyond). The 2033-2035 windows suggest a realistic path to or beyond $50 under the provided projections.
Current price is $11.34 and market cap is $820.74M. The stock is ranked 2541 in market capitalization.
The 30-day range is from $7.92 to $16.24, illustrating the recent volatility and the price levels the stock has traded within over the past month.
Omeros Corporation Community Discussion
0Share your Omeros Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.